7th Annual MarketsandMarkets

Next-Gen Immuno-Oncology Conference

20th - 21st June 2024

Boston, USA

Our 7th Annual MarketsandMarkets Next Gen Immuno-Oncology Conference to be held on 20th - 21st June 2024, in Boston, USA would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in the development of ADCs, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccine development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions. With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in the development of ADCs, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy

CO-LOCATED CONFERENCES

2nd Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference - East Coast Edition

WHAT TO EXPECT

  • Updates in development of ADC’s and Bispecific Ab’s
  • Immune Checkpoint Inhibitors and Combinations
  • Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
  • Biomarkers and Personalized Medicine in IO
  • CAR-T Cell therapy, TCR Based-Cell Therapy
  • Tumor microenvironment and Oncolytic Viruses

  • Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
  • Find out new case studies of immune-oncology projects in development
  • Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
  • Explore the latest platforms and technologies on the market for development
  • Discuss the best tool for your research in immune-oncology
  • Share your work and achievements with your industry peers in the Poster Session

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

  • Monoclonal and Bispecific Antibodies
  • Cell Therapy
  • Immune Checkpoint Inhibitors

CONFERENCE AGENDA

Registration

08:15 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

Keynote Presentation (Reserved for Platinum Sponsor)

09:00 - 09:30

ADC drug and its applications

Siamak Tabrizi

Siamak Tabrizi, Senior Scientist, Immunitas Therapeutics

09:30 - 10:00

Reserved Slot for Gold Sponsor

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Reserved Slot for Silver Sponsor

11:15 - 11:45

SUPLEXA therapeutic cells, a clinically derisked cell therapy platform with unique mechanisms of action for treating solid cancers

Frank Borriello

Frank Borriello, Founder and CEO, Alloplex Biotherapeutics

11:45 - 12:15

Bispecific T-Cell engagers for cancer immunotherapy

12:15 - 12:45

Precision Immunology for targeted therapy

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Improving efficacy of CPI’s by selected combination therapy

14:15 - 14:45

Novel mRNA-based Immunotherapy Vaccines

14:45 - 15:15

Oncolytic viruses in the era of Checkpoint Blockade

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Challenges and Opportunities for the development of ADCs, bispecific immunomodulatory therapies, and combination

Rakesh Dixit

Rakesh Dixit, CEO, Bionavigen

16:30 - 17:00

Panel Discussions - Innovations in Immunotherapy: Unravelling the Trifecta - Precision Immunology, Cancer Microbiome, and CAR-T Cell Therapy for Personalized Cancer Treatment

17:00 - 17:30

Closing Remarks from the Chairperson

17:30 - 17:30

Registration

08:15 - 08:55

Opening Remarks from the Chairperson

08:55 - 09:00

Keynote Presentation (Reserved for Platinum Sponsor)

09:00 - 09:30

Innovative Preclinical Models for Investigating Tumor-Immune Interactions

09:30 - 10:00

Solution Provider Presentation (Reserved for Gold Sponsor)

10:00 - 10:30

Morning Refreshments and Poster Presentation | One-to-One Networking Meetings

10:30 - 11:15

Solution Provider Presentation (Reserved for Silver Sponsor)

11:15 - 11:45

Translational approach in developing right IO therapy

11:45 - 12:15

Development of new generation DNA vaccines

12:15 - 12:45

Combination Strategies to Overcome Resistance to Anti-PD-1/PD-L1 Therapies

12:45 - 13:15

Lunch and Poster Presentation | One-to-One Networking Meetings

13:15 - 14:15

Future opportunities in clinical development of ICI’s

14:15 - 14:45

The Intersection of Immunology and Oncology: Advancing Targeted Therapy Paradigms

14:45 - 15:15

Challenges and Opportunities in Validating Preclinical Models for Immuno-Oncology Drug Development

15:15 - 15:45

Afternoon Refreshments and Poster Presentation | One-to-One Networking Meetings

15:45 - 16:30

Panel Discussion: Immunotherapy Frontiers: Integrating Precision Immunology, Cancer Microbiome, and CAR-T Therapies for Tailored Patient Care

16:30 - 17:00

Closing Remarks from the Chairperson

17:00 - 17:00

SPEAKERS

Siamak Tabrizi

Siamak Tabrizi

Senior Scientist, Immunitas Therapeutics

Claudio Scuoppo

Claudio Scuoppo

Principal Scientist, Sapience Therapeutics

Rakesh Dixit

Rakesh Dixit

CEO, Bionavigen

Frank Borriello

Frank Borriello

Founder and CEO, Alloplex Biotherapeutics

Neelam Bhardwaj

Neelam Bhardwaj

Product Development Lead, Novartis

ENQUIRE NOW

SPONSORS

LOCATION

Venue

Boston, USA

PAST EVENT GALLERY